CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.

Nuklearmedizin · 2024 · PMC10963126 · PMID 38190998

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, an elevated CXCR4-PET signal showed a trend towards shorter progression-free survival, suggesting that [ 68 Ga]Ga-PentixaFor may also represent a prognostic biomarker with regard to disease progression and need for improved/intensified treatment 14 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.